📈 Trending 🗄 Archive 💬 Ask ＋ Join⌂ House

Loop Biotech

biology, engineered

Live · refreshes automatically

⚡ The Brief - today's Biotech, synthesized
Top story FDA accepts uniQure's AMT-130 for priority review, sets May 2027 decision on Huntington's gene therapy
Biopharmadive

A May 2027 PDUFA date and a likely advisory committee make this the furthest-advanced gene therapy for Huntington's disease, based on a small externally controlled dataset.

full coverage →fdagene-therapyhuntingtons
GlobenewswireuniQure Announces FDA Acceptance and Priority Review of theHuntingtonsdiseasenewsFDA grants priority review to gene therapy for Huntington’sYahooUniQure gets an FDA decision date; Teva scraps brain drug studyPharmaphorumuniQure set for May FDA verdict on Huntington's gene therapyDealroomFDA accepts uniQure's Huntington's gene therapy for priority reviewNeurologyliveFDA Grants Priority Review to Huntington Disease Gene Therapy BLAFiercebiotechFDA grants uniQure’s Huntington’s gene therapy priority review, teeing up ‘defining milestone’HdbuzzFDA sets May 2027 decision date on AMT-130 gene therapy for HDGurufocusuniQure's Gene Therapy BLA for Huntington's Disease Gains FDA PrAllsciFDA grants uniQure’s Huntington’s gene therapy Priority Review on small, externally controlled datasetGenengnewsFDA Sets May 1 PDUFA Action Date for uniQure’s Huntington’s Disease Gene TherapyWtvbamFDA to review uniQure’s Huntington’s gene therapy, decision due on May 2027BiopharminternationalFDA Accepts uniQure’s Huntington’s Disease Gene Therapy BLA for Priority ReviewTradingviewuniQure gains FDA Priority Review for Huntington's disease gene therapyMuggleheaduniQure gains FDA priority review for Huntington's gene therapy
FDA grants accelerated approval to Inovio's DNA immunotherapy Voceryq for rare HPV-linked airway disease
Fiercepharma

The first DNA-based therapy approval marks a shift in the field from vaccines toward therapeutic use in recurrent respiratory papillomatosis.

full coverage →fdadna-medicineapproval
BiopharminternationalFDA Grants Accelerated Approval to Inovio DNA Immunotherapy for RRPEndpointsUniQure gets review date and adcomm; Inovio’s stock surges after approvalThepharmaletterInovio rockets as it wins FDA approval of VoceryqChosunFda grants first dna therapy approval, shifting focus from vaccines to treatmentMedpagetodayNovel Therapy Lands Speedy Approval for Wart-Like Airway DiseaseMedicaldailyNew DNA-based therapy offers adults with recurrent HPV airway disease an alternative to repeated surgeriesPharmacytimesFDA Grants Accelerated Approval to First Plasmid DNA-Based Immunotherapy for Recurrent Respiratory PapillomatosisBiospaceINOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)MedcitynewsInovio’s DNA-Based Immunotherapy Lands Speedy FDA Nod for Rare Type of TumorBiggoFDA Clears First DNA-Based Therapy, Inovio's Voceryq, for Rare Airway DiseaseDealroomInovio wins FDA accelerated approval for Voceryq, first DNA immunotherapy for rare airway disease RRPStreetinsiderFDA grants accelerated approval to Inovio's VOCERYQ for rare airway disease
Bright Minds' Phase 2 DEE epilepsy trial halted as FDA imposes partial clinical hold on BMB-101
Dealroom

The hold, tied to toxicity seen in mice, cut the biotech's share price roughly in half and delays its lead seizure program.

full coverage →fdaclinical-holdepilepsy
FiercebiotechFDA dims Bright Minds’ outlook with partial hold on seizure trial over toxicity in miceAllsciBright Minds' Phase II DEE seizure trial blocked by FDA partial clinical hold on BMB-101ScanxFDA places partial clinical hold on Bright Minds' BMB-101 trialGurufocusFDA Imposes Partial Clinical Hold on Bright Minds Biosciences (DMuggleheadBright Minds Biosciences reports FDA partial hold on BMB‑101 seizure trialClinicaltrialvanguardBright Minds’ BMB-101 Hold Exposes a Recurring Failure in Preclinical-to-IND TranslationStocktitanThe FDA put Bright Minds' planned seizure study partly on hold, citing toxicity findings in mice.MSNFDA puts partial hold on Bright Minds’ Phase II seizure study
FDA approves Bayer's Kerendia to slow chronic kidney disease in type 1 diabetes
Scanx

The label expansion extends the nonsteroidal MRA beyond type 2 diabetes to a broader CKD population.

full coverage →fdaapprovalkidney-disease
HcpliveFDA Approves Finerenone (Kerendia) for CKD and Type 1 DiabetesPharmexecFDA Approves Kerendia for Adults with Chronic Kidney Disease and Type 1 DiabetesAjmcFDA Expands Finerenone Approval to CKD Associated With Type 1 DiabetesFiercepharmaBayer’s Kerendia secures FDA nod as first drug in 30 years for Type 1 diabetes-associated kidney diseaseDrugtopicsFDA Approves Finerenone for Chronic Kidney Disease With Type 1 DiabetesHealioFDA approves Kerendia for adults with CKD associated with type 1 diabetesBreakthrought1dFinerenone Approved for Chronic Kidney Disease Associated With T1DEuropeanpharmaceuticalreviewBayer’s Kerendia approved in US as first new CKD and type 1 diabetes therapy in three decadesAllsciFDA expands Bayer’s Kerendia to type 1 diabetes-associated chronic kidney diseaseDealroomBayer's Kerendia wins FDA nod as first new treatment in 30 years for kidney disease in type 1 diabetesBayerFDA approves KERENDIA® as first new CKD treatment in 30 years for adults with type 1 diabetesMedicaldialoguesFDA Approves Finerenone for CKD Associated With Type 1 DiabetesIndianpharmapostBayer’s Kerendia wins FDA nod for chronic kidney disease linked to Type 1 diabetesBiospaceBayer’s KERENDIA® (finerenone) Receives U.S. FDA Approval for Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes
Lilly's Jaypirca wins FDA approval for first-line CLL/SLL treatment
Scanx

The front-line clearance expands use of the BTK inhibitor into newly diagnosed chronic lymphocytic leukemia patients.

full coverage →fdaapprovaloncology
FiercepharmaWith FDA approval, Lilly’s BTK drug Jaypirca enters first-line CLLPrnewswireLilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLLPharmexecEMA’s CHMP Recommends Eli Lilly’s Jaypirca for ApprovalYahooEli Lilly (LLY) Wins EMA Backing For Jaypirca In Chronic Lymphocytic LeukemiaMuggleheadEli Lilly and Company wins first-line Jaypirca approval for CLL/SLLStreetinsiderFDA approves Lilly's Jaypirca for first-line CLL/SLL treatment
BioNTech beats Q3 estimates, holds to mRNA cancer strategy despite trial misses
Genomeweb

The company reported Q3 revenue above estimates and reiterated its commitment to mRNA cancer therapies after a mixed month of data.

full coverage →earningsmrnabiontech
InvestingEarnings call transcript: BioNTech beats Q3 2026 estimates as stock rises premarketAd-hoc-newsBioNTech's October Ledger: A Lung-Cancer Signal, a Modest Breast-Cancer Win, and a Missed mRNA EndpoNprWhat the latest on mRNA vaccines means for cancer247wallstModerna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds SteadyMSNBioNTech Q3 2026 earnings call transcript
Vertex executives defend povetacicept launch outlook ahead of FDA decision in IgA nephropathy
Biopharmadive

Wall Street views the IgA nephropathy drug as central to Vertex's pipeline, and management used its earnings call to calm investor concerns.

full coverage →vertexkidney-diseaseearnings
TradingviewVRTX Q3 deep dive: Pipeline, product launches, and Crinetics integration shape outlookTikrVertex Pharmaceuticals Rose 7% Today. Here’s Where the Stock Is Headed in 2026YahooVertex Pharmaceuticals Q3 Earnings Call Highlights
Child dies of measles in New York, the state's first such death in 30 years
STAT

The death in rural northern New York underscores slipping vaccination coverage amid national measles outbreaks.

full coverage →public-healthmeaslesvaccines
The New York TimesChild Dies From Measles in New York State’s First Fatal Case in 30 YearsMedpagetodayChild Dies of Measles in New York's First Such Death in 30 YearsThe GuardianNew York child dies from measles in state’s first fatal case in 30 yearsAPChild dies of measles in New York’s first such death in 30 yearsWsoctvChild dies from measles in New York, the state’s first fatal case in 30 yearsTimesunionUpstate child’s measles death is NY’s first in decadesCnnChild in New York dies after contracting measles, the state’s first such death in 30 years13whamChild dies after contracting measles in upstate NY, first such death in over 30 yearsCrainsnewyorkChild dies of measles in rural New York, marking state’s first death in over 30 yearsBaltimoresunChild dies after contracting measles in NY, first such death in more than 30 yearsLatintimesNew York records first measles death in more than 30 years as vaccination coverage falls below level neededWashingtonpostNew York reports its first measles-associated death in more than 30 yearsSanNew York child dies of measles amid worst outbreak in 35 yearsHeraldbannerChild dies of measles in New York's first such death in 30 years
Washington state resident dies of bird flu after cattle exposure, first U.S. death this year
STAT

The third U.S. H5N1 death overall raises fresh questions about surveillance of the virus in dairy herds.

full coverage →public-healthbird-fluh5n1
GlobalbiodefenseBird Flu Kills Yakima County Resident Exposed at Dairy, First U.S. Death This YearDiscovermagazineFirst U.S. Bird Flu Death of 2026 Confirmed Following Washington Resident's Exposure to Infected Dairy CowsYahooFirst US bird flu death in a year-map shows where dairy herds are infectedThe GuardianWashington state resident dies from ‘severe illness’ after contracting bird fluBaltimoresunOfficials report first bird flu death in US in 2026, say public risk is lowNewserWashington State Resident Dies From Bird FluAgdailyYakima County resident dies after contracting bird flu on dairy farmNypostWashington state resident dies after contracting bird flu from dairy farm: officialsContagionliveWashington State Reports First US Avian Influenza Death of 2026MedicaldailyFirst U.S. bird flu death of 2026 linked to infected dairy cattle exposurePeopleWashington Resident Dies of Bird Flu After Dairy Exposure, First U.S. Fatality of 2026SpokesmanWA records first bird flu death of 2026EdairynewsWashington State Resident Dies After Contracting Avian Influenza On Dairy Farm: Health Officials
Medicare Part D premiums to jump 50% on average next year, KFF finds
Biopharmadive

KFF urged seniors to shop carefully during open enrollment given wide cost variance between plans.

full coverage →medicaredrug-pricingpolicy
HealthcarediveMedicare Part D premiums are spiking 50% on average next year, KFF findsMarketWatchMedicare prescription drug costs will jump 50% in 2027. Doing nothing could cost you.MedicaldailyStand-Alone Medicare Drug Plan Premiums Could Jump 50% in 2027, and No $0 Plans Will Be OfferedRamaonhealthcareMedicare Part D premiums are spiking 50% on average next year, KFF findsAarp2027 Cost Concerns for Medicare Advantage, Part DKffhealthnewsBreaking Down Why Medicare Part D Premiums Are Likely To Go UpKffMedicare Part D in 2024: A First Look at Prescription Drug Plan Availability, Premiums, and Cost SharingHealthsystemtrackerHow much and why ACA Marketplace premiums are going up in 2026InklMedicare changes and rising health costs are top of mind for older voters as Election Day nearsMSNMedicare prescription drug costs will jump 50% in 2027. Doing nothing could cost you.
FDA finalizes cell and gene therapy potency guidance
Raps

The guidance gives developers a standardized framework for potency assays, a long-running bottleneck in CGT approvals.

full coverage →fdaguidancecell-therapy
OncodailyFDA Issues New Guidance on Cell and Gene Therapy PotencyVohnetworkUS FDA Issues Final Guidance to Strengthen Cell and Gene Therapy Quality StandardsThepharmaletterFDA provides guidance for cell and gene therapy developmentBiospacePlug-and-play gene therapy: FDA executes on vision that’s been in the works for yearsTargetedoncFDA Finalizes Potency Guidance for Cell and Gene Therapy ProductsBiopharminternationalFDA Finalizes Potency Assurance Guidance for Cell and Gene TherapiesAllsciFDA finalizes risk-based potency strategy guidance for cell and gene therapy productsCgtliveFDA Finalizes Sets of Guidelines for Both CAR-T Products and Genome Editing ProductsTargetedoncFDA Finalizes Potency Guidance for Cell and Gene Therapy Products
FDA approves generic lenacapavir HIV prevention shot, widening access for lower-income countries
STAT

Tentative approval for Dr. Reddy's generic version of the twice-yearly shot is a key step in broadening global PrEP access.

full coverage →hivgenericsglobal-health
SpectrumlocalnewsCheap lenacapavir HIV-prevention shot approved, raising hopes in poor countriesCapitalfmGeneric HIV prevention injection moves closer to 120 countries after FDA approvalBusiness-standardApproval of India-made HIV-prevention shot raises hopes in poorer nationsBoldnewsonlineIndia-Made Lenacapavir Approval Raises Hopes for Affordable HIV Prevention in Poorer NationsDemokratisFDA Approves Generic HIV Prevention Shot for 120 CountriesReutersDr Reddy's gets tentative US FDA nod for generic HIV preventionGileadAccess Strategy for Long-Acting PrEPYahooUS approves cheap generic of breakthrough HIV shot for poorer countriesManagedhealthcareexecutiveNation’s largest AIDS Drug Assistance Program hit in Florida, other states follow suitGayetyGeneric Lenacapavir Wins FDA Tentative Approval, but U.S. Yeztugo Users Can’t Switch YetSpringerLenacapavir for HIV PrEP: Narrative Review of Clinical Trials and Implications for Patient AccessOsundefenderUS Approves Cheap Version Of HIV Prevention ShotChronicleUS approves cheap version of HIV prevention shot for 120 countriesK24Cheaper version of HIV prevention shot gets approval
FDA advisers narrowly vote to add six peptides to the drug compounding list
Ajmc

The close vote keeps alive a fight over compounded peptides such as BPC-157 and semaglutide copies.

full coverage →fdacompoundingpeptides
PbsWATCH: FDA advisory panel narrowly backs use of several peptides favored by RFK Jr.RapsFDA advisory committee backs two more peptides, rejects one for compounding listSTATFDA advisory panel narrowly rejects compounding of one peptide, backs two othersSafemedicinesJuly 27, 2026: FDA peptide panel narrowly votes to add unapproved drugs to compounding listHealthaffairsFDA Advisory Committee’s Vote May Open A Drug-Compounding Back Door For Unapproved PeptidesPharmexecFDA Panel Votes to Loosen Restrictions for Four PeptidesJdsupraPeptides: HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides
The daily briefTop stories, once a day. Or build your own feed.